Intravenous with intrathecal interferon in subacute sclerosing panencephalitis

K. P S Nair, H. S. Swamy, G. R. Arunodaya, V. Ravi, A. B. Taly

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Recent literature from different countries has revealed variable results of interferon treatment in subacute sclerosing panencephalitis (SSPE). Twelve patients with SSPE were treated at NIMHANS by concurrent use of intravenous and intrathecal interferon ALFA-2a, manufactured by recombinant DNA technology. The diagnosis of SSPE was based on clinical profile, EEG, CT and presence of anti measles IgG antibodies in CSF. The total dose of interferon by intrathecal as well as intravenous route varied from 15 million to 60 million units. Clinical improvement as demonstrated by a decrease in scores on Neurological disability index occurred in three. Two of them relapsed five months after stopping the therapy but one patient maintained improvement two years after stopping treatment. There was no significant change in six patients. There were 3 deaths. One of them was autopsied. A decrease in titres of antimeasles antibody in CSF was noted in two patients who showed clinical improvement, but in others there was no consistent correlation. No significant changes occurred in EEG during the treatment period. No serious side effect of interferon were encountered. Two patients had iatrogenic meningitis which could be treated successfully. Use of intravenous combined with intrathecal interferon is not promising in SSPE.

Original languageEnglish
Pages (from-to)20-25
Number of pages6
JournalNeurology India
Volume43
Issue number1
Publication statusPublished - 1995

Fingerprint

Subacute Sclerosing Panencephalitis
Interferons
Electroencephalography
Recombinant DNA
Antibodies
Measles
Therapeutics
Meningitis
Technology

Keywords

  • CT
  • measles
  • recombinant interferon
  • slow virus diseases
  • subacute sclerosing panencephalitis

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Nair, K. P. S., Swamy, H. S., Arunodaya, G. R., Ravi, V., & Taly, A. B. (1995). Intravenous with intrathecal interferon in subacute sclerosing panencephalitis. Neurology India, 43(1), 20-25.

Intravenous with intrathecal interferon in subacute sclerosing panencephalitis. / Nair, K. P S; Swamy, H. S.; Arunodaya, G. R.; Ravi, V.; Taly, A. B.

In: Neurology India, Vol. 43, No. 1, 1995, p. 20-25.

Research output: Contribution to journalArticle

Nair, KPS, Swamy, HS, Arunodaya, GR, Ravi, V & Taly, AB 1995, 'Intravenous with intrathecal interferon in subacute sclerosing panencephalitis', Neurology India, vol. 43, no. 1, pp. 20-25.
Nair, K. P S ; Swamy, H. S. ; Arunodaya, G. R. ; Ravi, V. ; Taly, A. B. / Intravenous with intrathecal interferon in subacute sclerosing panencephalitis. In: Neurology India. 1995 ; Vol. 43, No. 1. pp. 20-25.
@article{0d88264c222d4b59a2f8b46ddbc77744,
title = "Intravenous with intrathecal interferon in subacute sclerosing panencephalitis",
abstract = "Recent literature from different countries has revealed variable results of interferon treatment in subacute sclerosing panencephalitis (SSPE). Twelve patients with SSPE were treated at NIMHANS by concurrent use of intravenous and intrathecal interferon ALFA-2a, manufactured by recombinant DNA technology. The diagnosis of SSPE was based on clinical profile, EEG, CT and presence of anti measles IgG antibodies in CSF. The total dose of interferon by intrathecal as well as intravenous route varied from 15 million to 60 million units. Clinical improvement as demonstrated by a decrease in scores on Neurological disability index occurred in three. Two of them relapsed five months after stopping the therapy but one patient maintained improvement two years after stopping treatment. There was no significant change in six patients. There were 3 deaths. One of them was autopsied. A decrease in titres of antimeasles antibody in CSF was noted in two patients who showed clinical improvement, but in others there was no consistent correlation. No significant changes occurred in EEG during the treatment period. No serious side effect of interferon were encountered. Two patients had iatrogenic meningitis which could be treated successfully. Use of intravenous combined with intrathecal interferon is not promising in SSPE.",
keywords = "CT, measles, recombinant interferon, slow virus diseases, subacute sclerosing panencephalitis",
author = "Nair, {K. P S} and Swamy, {H. S.} and Arunodaya, {G. R.} and V. Ravi and Taly, {A. B.}",
year = "1995",
language = "English",
volume = "43",
pages = "20--25",
journal = "Neurology India",
issn = "0028-3886",
publisher = "Medknow Publications and Media Pvt. Ltd",
number = "1",

}

TY - JOUR

T1 - Intravenous with intrathecal interferon in subacute sclerosing panencephalitis

AU - Nair, K. P S

AU - Swamy, H. S.

AU - Arunodaya, G. R.

AU - Ravi, V.

AU - Taly, A. B.

PY - 1995

Y1 - 1995

N2 - Recent literature from different countries has revealed variable results of interferon treatment in subacute sclerosing panencephalitis (SSPE). Twelve patients with SSPE were treated at NIMHANS by concurrent use of intravenous and intrathecal interferon ALFA-2a, manufactured by recombinant DNA technology. The diagnosis of SSPE was based on clinical profile, EEG, CT and presence of anti measles IgG antibodies in CSF. The total dose of interferon by intrathecal as well as intravenous route varied from 15 million to 60 million units. Clinical improvement as demonstrated by a decrease in scores on Neurological disability index occurred in three. Two of them relapsed five months after stopping the therapy but one patient maintained improvement two years after stopping treatment. There was no significant change in six patients. There were 3 deaths. One of them was autopsied. A decrease in titres of antimeasles antibody in CSF was noted in two patients who showed clinical improvement, but in others there was no consistent correlation. No significant changes occurred in EEG during the treatment period. No serious side effect of interferon were encountered. Two patients had iatrogenic meningitis which could be treated successfully. Use of intravenous combined with intrathecal interferon is not promising in SSPE.

AB - Recent literature from different countries has revealed variable results of interferon treatment in subacute sclerosing panencephalitis (SSPE). Twelve patients with SSPE were treated at NIMHANS by concurrent use of intravenous and intrathecal interferon ALFA-2a, manufactured by recombinant DNA technology. The diagnosis of SSPE was based on clinical profile, EEG, CT and presence of anti measles IgG antibodies in CSF. The total dose of interferon by intrathecal as well as intravenous route varied from 15 million to 60 million units. Clinical improvement as demonstrated by a decrease in scores on Neurological disability index occurred in three. Two of them relapsed five months after stopping the therapy but one patient maintained improvement two years after stopping treatment. There was no significant change in six patients. There were 3 deaths. One of them was autopsied. A decrease in titres of antimeasles antibody in CSF was noted in two patients who showed clinical improvement, but in others there was no consistent correlation. No significant changes occurred in EEG during the treatment period. No serious side effect of interferon were encountered. Two patients had iatrogenic meningitis which could be treated successfully. Use of intravenous combined with intrathecal interferon is not promising in SSPE.

KW - CT

KW - measles

KW - recombinant interferon

KW - slow virus diseases

KW - subacute sclerosing panencephalitis

UR - http://www.scopus.com/inward/record.url?scp=0028910832&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028910832&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0028910832

VL - 43

SP - 20

EP - 25

JO - Neurology India

JF - Neurology India

SN - 0028-3886

IS - 1

ER -